Health Canada Approves Durvalumab Monotherapy for Limited-Stage Small Cell Lung Cancer
Durvalumab received approval from Health Canada for patients with LS-SCLC whose disease has not progressed after platinum-based chemoradiation.
Related Articles
Targeted Treatments Shift the Paradigm of Advanced BTC
During the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, an OncLive Peer Exchange® featured insights from expert investigators in the field of BTC.
Targeted Therapy Developments and Screening Updates Broaden the NSCLC Treatment Paradigm
Alexis Chidi, MD, PhD, MSPH, emphasizes the importance of having more available targeted therapies and explains NSCLC screening eligibility criteria.
Less Is More With Advanced Surgical Approaches in Early-Stage NSCLC
Alexis Chidi, MD, PhD, MSPH, details the evolution of surgical approaches in early-stage lung cancer, including wedge resections and segmentectomies.
Cilta-Cel Yields QOL Benefits and Prolonged Treatment-Free Intervals vs SOC in R/R Myeloma
Treatment with cilta-cel led to improvements across several QOL subscales compared with SOC therapy in patients with lenalidomide-refractory myeloma.
Tarlatamab Yields OS Improvement in SCLC After Platinum Progression
Tarlatamab improved overall survival vs chemotherapy in small cell lung cancer following progression on or after platinum-based chemotherapy.
FDA Approves Nivolumab Plus Ipilimumab for Unresectable or Metastatic Hepatocellular Carcinoma
The FDA has awarded full approval to frontline nivolumab plus ipilimumab for the treatment of adult patients with unresectable hepatocellular carcinoma.
PSMAfore Data Drive Expanded Approval of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC
Michael J. Morris, MD, discusses data from the PSMAfore trial that supported the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in mCRPC.
Dr Kuerer on Selective Surgery Omission After Response to Neoadjuvant Therapy in Invasive Breast Cancer
Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses a study on selective elimination of breast surgery after exceptional response to neoadjuvant therapy in early breast…
CEPHEUS Data Support D-VRd in Transplant-Ineligible or -Deferred Patients With Myeloma Who Can Tolerate Bortezomib
D-VRd has the potential to significantly improve clinical outcomes in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma.
OncLive’s FDA Approval Report: The Regulatory Rundown for April 2025
Here is your snapshot for all therapeutic options that were cleared by the FDA in April 2025 spanning tumor types.